238
Participants
Start Date
October 31, 2007
Primary Completion Date
December 31, 2014
Study Completion Date
December 31, 2014
Dasatinib
Dasatinib was supplied as 20- and 50-mg tablets.
Imatinib
Imatinib was supplied as 100- and 400-mg tablets.
Local Institution, Lima
Local Institution, Buenos Aires
Local Institution, Budapest
Local Institution, Buenos Aires
Local Institution, Capital Federal
Local Institution, Parktown
Local Institution, Basel
Local Institution, Adelaide
Local Institution, Mont-godinne
Local Institution, Trondheim
Local Institution, Orbassano (to)
Local Institution, Bangkok
Local Institution, Campinas
Western Pennsylvania Hospital, Pittsburgh
Local Institution, Lublin
Local Institution, Rio de Janeiro
Local Institution, Hamburg
Local Institution, Krakow
Local Institution, Pessac
H. Lee Moffitt Cancer Center & Research Institute, Tampa
Local Institution, Katowice
Local Institution, Bologna
Local Institution, Gothenburg
Local Institution, Nantes
Central Indiana Cancer Centers, Indianapolis
University Of Michigan Medical Center, Ann Arbor
Wayne State University, Detroit
Local Institution, Ramat Gan
Local Institution, Lille
University Of Chicago, Chicago
University Of Kansas Medical Center, Westwood
Local Institution, Strasbourg
Local Institution, Mannheim
Local Institution, Lyon
Ut Southwestern Medical Center At Dallas, Dallas
Local Institution, Paris
The University Of Texas Md Anderson Cancer Center, Houston
Local Institution, Curitiba
Local Institution, Napoli
Local Institution, Poitiers
Ucla Department Of Medicine, Los Angeles
Loma Linda University Cancer Center, Loma Linda
Pacific Cancer Medical Center Inc, Anaheim
Stanford University School Of Medicine, Stanford
Kaiser Permanente Medical Center, Vallejo
Oregon Health & Sci Univ, Portland
Local Institution, Moscow
Local Institution, Saint Petersburg
Dana Faber Cancer Institute, Boston
John Theurer Cancer Center, Hackensack
Local Institution, São Paulo
Local Institution, São Paulo
Local Institution, Toronto
Local Institution, Montreal
Local Institution, Helsinki
Local Institution, Leipzig
Local Institution, Dublin
Local Institution, Roma
Local Institution, Lima
Local Institution, Lodz
Local Institution, Warsaw
Local Institution, Groenkloof
Local Institution, Jeollanam-do
Local Institution, Seoul
Local Institution, Barcelona
Local Institution, Lund
Local Institution, Stockholm
Local Institution, Umeå
Local Institution, Uppsala
Local Institution, London
Local Institution, Glasgow
Local Institution, Newcastle
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY